Concepedia

Drew Dudgeon

DD

9

Publications

651

Citations

9

H-Index

2018

Active since

Affiliations

Regeneron (United States)(Current)

Progenics Pharmaceuticals (United States)

Drew Dudgeon is an author at Regeneron (United States) specializing in immunotherapy, immunology, and medicine.

ORCID

Top concepts

Publications per year

2018–2024

9

Publications

9

Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates

Kristen E. Pascal, Drew Dudgeon, John C. Trefry et al. · The Journal of Infectious Diseases · 2018 · 178 citations · Full text

A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies

Dimitris Skokos, Janelle Waite, Lauric Haber et al. · Science Translational Medicine · 2020 · 141 citations

Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning

Lauric Haber, Kara Olson, Marcus P. Kelly et al. · Scientific Reports · 2021 · 93 citations · Full text

Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy

Janelle Waite, Bei Wang, Lauric Haber et al. · Science Translational Medicine · 2020 · 88 citations

Preclinical PET imaging with the novel human antibody <sup>89</sup>Zr-DFO-REGN3504 sensitively detects PD-L1 expression in tumors and normal tissues

Marcus P. Kelly, Sosina Makonnen, Carlos Hickey et al. · Journal for ImmunoTherapy of Cancer · 2021 · 42 citations · Full text

Rows per page

1–5 of 9